RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Crown Biosciences, a global CRO, in-licensed rights to translational platforms from Shanghai Model Organisms Center (SMOC). The genetically engineered mouse models include proprietary transgenic and reporter models for oncology, cardiovascular and immunology research. SMOC said the agreement will make its products available globally. In December 2017, CrownBio was acquired by JSR Corporation of Japan for $400 million. The CRO has facilities in China, the US, the UK and Taiwan.
Source: China Biotoday